Sort by

Send to

Choose Destination

Search results

Items: 4


Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.


Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.

Lübbe J, Friedlander SF, Cribier B, Morren MA, García-Díez A, Gelmetti C, Hofmann H, Houwing RH, Kownacki S, Langley RG, Virtanen M, Wolff K, Wisseh S, McGeown C, Abrams B, Schneider D; NOBEL (New Online Based ELidel) Study Group.

Am J Clin Dermatol. 2006;7(2):121-31.


A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.

Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S, Abrams B.

J Am Acad Dermatol. 2004 Oct;51(4):515-25.


From concept to application: the impact of a community-wide intervention to improve the delivery of preventive services to children.

Margolis PA, Stevens R, Bordley WC, Stuart J, Harlan C, Keyes-Elstein L, Wisseh S.

Pediatrics. 2001 Sep;108(3):E42.


Supplemental Content

Loading ...
Support Center